Protara Therapeutics, Inc. (TARA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.94-0.76%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TARA
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||||
| Revenues | — | — | — | — | — | — | — | — | — | — | 2.9 | 2.9 | 2.9 |
| Total Revenues | — | — | — | — | — | — | — | — | — | — | 2.9 | 2.9 | 2.9 |
| Operating Expenses & Income | |||||||||||||
| R&D Expenses | 53.2 | 42.6 | 31.7 | 25.0 | 16.8 | 21.1 | 12.0 | 3.9 | 11.8 | 21.7 | 18.9 | 12.4 | 6.4 |
| Operating Income | (76.8) | (64.5) | (49.2) | (43.6) | (67.1) | (47.5) | (34.4) | (7.8) | (21.4) | (30.4) | (28.7) | (20.9) | (7.6) |
| Earnings from Continuing Operations | |||||||||||||
| Interest Expense | — | — | — | — | — | 0.0 | 0.0 | — | — | — | — | — | 0.9 |
| Interest & Investment Income | 6.5 | 6.4 | 4.2 | 3.2 | 1.1 | 0.2 | 0.5 | — | — | — | — | — | — |
| Net Interest Expenses | — | — | — | — | — | (0.2) | (0.5) | — | — | — | — | — | — |
| Other Non-Operating Income / Expenses | 6.8 | 7.1 | 4.6 | 3.2 | 1.1 | 0.2 | 0.5 | 0.3 | 0.6 | 0.4 | 0.2 | (0.5) | 4.2 |
| EBT, Incl. Unusual Items | — | 57.4 | — | — | — | — | — | (15.0) | (20.7) | (30.0) | (28.5) | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — | — | — | — | — | (0.1) |
| Net Income | |||||||||||||
| Net Income | (70.0) | (57.4) | (44.6) | (40.4) | (66.0) | (47.3) | (34.0) | (7.8) | (20.7) | (30.0) | (28.5) | (21.4) | (3.3) |
| Per Share | |||||||||||||
| Basic EPS | (1.15) | (1.34) | (2.17) | (3.57) | (5.86) | (4.21) | — | — | — | — | — | — | — |
| Diluted EPS | (1.15) | (1.34) | (2.17) | (3.57) | (5.86) | (4.21) | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 61.0 | 42.8 | 20.6 | 11.3 | 11.3 | — | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 61.0 | 42.8 | 20.6 | 11.3 | 11.3 | 11.2 | — | — | — | — | — | — | — |
| Supplemental | |||||||||||||
| EBITDA | — | — | — | — | — | — | — | — | — | — | (28.6) | (20.8) | (7.6) |
| EBIT | (76.8) | (64.5) | (49.2) | (43.6) | (67.1) | (47.5) | (34.4) | (7.8) | (21.4) | (30.4) | (28.7) | (20.9) | (7.6) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.